Analysts lifted targets across several key names on Thursday. Technology and healthcare dominated the upgrades.
Datadog saw its consensus target rise to $269.97 from $268.55. The cloud monitoring firm carries an $87 billion market cap. Analysts remain overwhelmingly bullish with 42 buy-equivalent ratings. Short interest sits at just 3.9% of free float — bears are not pressing this name.
DexCom drew a more dramatic target re-rate. The average price target jumped to $90.88 from $86.16 — a nearly $5 move higher. The diabetes device maker now commands a $29 billion market cap. It holds 25 sell-side analysts. Only one rates it a buy, suggesting room for upgrades to follow.
On the downside, Builders FirstSource saw its target cut to $83.45 from $87.60. Housing market pressure likely weighs on the building materials distributor. Short interest at 6.2% of free float is moderate but worth watching.
Valero Energy enjoyed a notable target lift. Analysts pushed the average to $300.47 from $290.22. The refiner's 3 buy ratings versus 10 sells suggest the Street is cautious, yet the target move signals improving refining margin expectations.
Bristol-Myers Squibb also saw its target edge up to $64.83 from $63.96, a quiet positive revision for the pharma giant.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
